Abstract
The κ-opioid receptor antagonist nor-binaltor-phimine (nor-BNI) was recently shown to potentiate certain overt withdrawal signs in morphine-dependent rats. The present study sought to further assess this phenomenon by examining the influence of nor-BNI treatment upon the conditioned place aversion associated with the naloxone-precipitated withdrawal syndrome. In addition, in vivo microdialysis studies were conducted in morphine-dependent rats to determine whether nor-BNI treatment can modify withdrawal-induced changes in basal dopamine (DA) release within the mesolimbic system. Rats were pretreated with either saline or a single dose of nor-BNI and then received ascending doses of morphine for 10 days. A withdrawal syndrome was then precipitated by the administration of naloxone (1 mg/kg SC). In rats which received chronic morphine injections, administration of naloxone produced a characteristic withdrawal syndrome and a marked aversion for an environment previously associated with naloxone-precipitated withdrawal. Nor-BNI treatment potentiated most overt signs of physical dependence. This treatment also resulted in a greater withdrawal-induced place aversion. Morphine-dependent rats exhibited a marked reduction in basal mesolimbic DA release. An even greater decrease in basal DA release was observed in nor-BNI treated rats. These results suggest that endogenous κ-systems are important in the modulation of mesolimbic DA release and the accompanying place aversion which occurs during opiate withdrawal.
Similar content being viewed by others
References
Aceto MD, Dewey WL, Chang JK, Lee NM (1982) Dynorphin-(1-13): effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83:139–142
Acquas E, Di Chiara G (1992) Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 58:1620–1625
Acquas E, Carboni E, Di Chiara G (1991) Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol 193:133–134
Bläsig J, Herz A, Reinhold K, Zieglgänsberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33:19–38
Chavkin C, James IF, Goldstein A (1982) Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215:413–415
Di Chiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067–1080
Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn 316:30–42
Green PG, Lee NM (1988) Dynorphin A-(1–13) attenuates withdrawal in morphine-dependent rats: effects of route of administration. Eur J Pharmacol 145:267–272
Hand TH, Koob GF, Stinus L, Le Moal M (1988) Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. Brain Res 474:364–368
Heijina MN, Padt M, Hogenboom F, Portoghese PS, Mulder AH, Schoffelmeer ANM (1990) Opioid receptor mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex. Eur J Pharmacol 18:267–278
Herz A, Shippenberg TS (1989) Neurochemical aspects of addiction: opioids and other drugs of abuse. In: Goldstein A (ed) Molecular and cellular aspects of drug adddiction. Springer, New York, pp 111–141
Higgins GA, Nguyen P, Joharchi N, Sellers EM (1991) Effects of 5-HT3 receptor antagonists on behavioural measures of nalox-one-precipitated opioid withdrawal. Psychopharmacology 105:322–328
Horan P, Taylor J, Yamamura HI, Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237–1243
Jackisch R, Hotz H, Hertting G (1993) No evidence for presynaptic opioid receptors on cholinergic, but presence of κ-receptors on dopaminergic neurons in the rabbit caudate nucleus: involvement of endogenous opioids. Naunyn-Schmiedeberg's Arch Pharmacol 348:234–241
Jones DNC, Holtzman SG (1992) Long term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 215:345–348
Koob GF, Wall TL, Bloom FE (1989) Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology 98:530–534
Magnan J, Paterson SJ, Tavani A, Kosterlitz (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 319:197–205
Maldonado R, Negus S, Koob GF (1992) Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology 31:1231–1241
Millan MJ, Morris BJ, Herz A (1988) Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists. J Pharmacol Exp Ther 247:721–728
Morris BJ, Millan MJ, Herz A (1988) Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography. J Pharmacol Exp Ther 247:729–736
Mucha RF, Herz A (1985) Motivational properties of Kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274–280
Portoghese PS, Lipkowski AW, Takemori AE (1987a) Bimorphinans as highly selective, potent κ opioid receptor antagonists. J Med Chem 30:238–239
Portoghese PS, Lipkowski AW, Takemori AE (1987b) Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci 40:1287–1292
Pothos E, Rada P, Mark GP, Hoebel BG (1991) Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 566:348–350
Rattan AK, Koo KL, Tejwani GA, Bhargava HN (1992) The effect of morphine tolerance, dependence and abstinence on immunoreactive dynorphin (1–13) levels in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of the rat. Brain Res 584:207–212
Romualdi P, Lesa G, Ferri S (1991) Chronic opiate agonists down regulate prodynorphin gene expession in rat brain. Brain Res 563:132–136
Rossetti ZL, Hmaidan Y, Gessa GL (1992) Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and ampetamine abstinence in rats. Eur J Pharmacol 221:227–234
Rothman RB (1992) A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12:129–138
Sesack SR, Pickel VM (1992) Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J Neurosci 12:1335–1350
Shippenberg TS, Bals-Kubik R, Herz A (1987) Motivational properties of opioids: evidence that an activation of delta receptors mediates reinforcement processes. Brain Res 436:234–239
Shippenberg TS, Herz A, Spanagel R, Bals-Kubik R, Stein C (1992) Conditioning of opioid reinforcement: neuroanatomical and neurochemical substrates. In: Kalivas PW, Samson HH (eds) The neurobiology of drug and alcohol addiction. Ann NY Acad Sci 654:347–356
Shippenberg TS, Bals-Kubik R, Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D1-1 versus D-2 dopamine receptors, J Pharmacol Exp Ther 265:53–59
Smith JAM, Loughlin SA, Leslie FM (1992) κ-Opioid inhibition of [3H] dopamine release from rat ventral mesencephalic dissociated cell cultures. J Pharmacol Exp Ther 42:575–583
Spanagel R, Shippenberg TS (1993) Modulation of morphine-induced sensitization by endogenous κ opioid systems in the rat. Neurosci Lett 153:232–236
Spanagel R, Herz A, Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55:1734–1740
Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS (1991) β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology 104:51–56
Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046–2050
Spyraki C, Fibinger HC, Phillips AG (1983) Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology 79:278–283
Stinus L, Le Moal M, Koob GF (1990) Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37:767–773
Suzuki T, Narita M, Misawa M, Nagase H (1990) Interaction between μ and kappa receptors in pharmacological effects of tolerance to and dependence on several opioids. J Pharmacobiodyn 13:s-133
Suzuki T, Narita M, Takahahi Y, Misawa M, Nagase H (1992) Effects of nor-binaltorphimine on the development of analgesic tolerance to and physical dependence on morphine. Eur J Pharmacol 213:91–97
Takemori AE, Ho BY, Naeseth JS, Portoghese PS (1988) Nor-binaltorphimine, a highly selective opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246:255–258
Takemori AE, Loh HH, Lee NM (1992) Supression by dynorphin A-(1–13) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221:223–226
Trujillo KA, Akil H (1990) Pharmacological regulation of striatal prodynorphin peptides. In: Van Ree JM, Mulder AH, Wiegant VM, van Wimersma Greidanus TB (eds) New leads in opioid research. Excerpta Medica, Amsterdam, pp 223–226
Wen HL, Ho WKK, Wen PYC (1984) Comparision of the effectiveness of different opioid peptides in suppressing opiate withdrawal. Eur J Pharmacol 100:155–161
Wise RA (1987) The role of reward pathways in the development of drug dependence. Pharmacol Ther 35:227–263
Wood PL, Charleson SE, Lane D, Hudgin RL (1981) Multiple opiate receptors: differential binding of μ κ and δ agonists. Neuropharmacology 20:1215–1220
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spanagel, R., Almeida, O.F.X., Bartl, C. et al. Endogenous κ-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 115, 121–127 (1994). https://doi.org/10.1007/BF02244761
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244761